The US Court of Appeals for the Federal Circuit has rejected Medtronic’s attempt to revisit a ruling that lumbered the medical device company with a $23 million loss.
The US Court of Appeals for the Federal Circuit affirmed a series of Patent Trial and Appeal Board inter partes reviews, which upheld a patent owned by Eli Lilly late last week.
The six antitrust class-action lawsuits that have been brought against AbbVie could result in more scrutiny of settlement agreements between the innovator and the biosimilar manufacturer, with potential antitrust complications.
US courts need to revisit the patentability of diagnostic tests under section 101, according to Memorial Sloan Kettering Cancer Center’s chief IP counsel.
Petitioners will continue to be able to launch litigation simultaneously before both the district court and the Patent Trial and Appeal Board, effectively having two bites at the apple, according to John Kirkland, director of IP at biopharmaceutical company Alkermes.
There’s alarm in the scientific community because of how broadly the principles of the Mayo test for section 101 are being used to strike down patents on profound innovations and discoveries.
The Delhi High Court has cleared two Indian drug companies to export a cancer drug and blood thinner, both patented by Bayer, for the purposes of development and clinical trials for regulatory clearances.
Biotech and pharmaceutical companies have submitted an amicus brief urging an appeals court to rethink a ruling, which invalidated a patent exclusively licensed by Athena Diagnostics.
Eli Lilly has entered into a $35m global licensing and research agreement with biotech company Avidity Biosciences.
A US health insurance provider is suing a subsidiary of Johnson & Johnson for filing “sham” patent litigation in a bid to stop generic forms of a prostate cancer treatment from entering the market.